Skip to main content

Peer Review reports

From: A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial

Original Submission
6 Apr 2020 Submitted Original manuscript
29 Jun 2020 Author responded Author comments - Collins Iwuji
26 May 2020 Reviewed Reviewer Report - Kristen Andreatta
30 May 2020 Reviewed Reviewer Report
Resubmission - Version 2
29 Jun 2020 Submitted Manuscript version 2
5 Jul 2020 Author responded Author comments - Collins Iwuji
Resubmission - Version 3
5 Jul 2020 Submitted Manuscript version 3
Publishing
7 Jul 2020 Editorially accepted
20 Jul 2020 Article published 10.1186/s12879-020-05240-y

You can find further information about peer review here.

Back to article page